Guru Fundamental Report for JNJ

Validea's P/B Growth Investor model, based on Partha Mohanram's strategy for identifying outperforming growth stocks, rated Johnson & Johnson (JNJ) at 77%. While JNJ, a large-cap pharmaceutical, passed most fundamental criteria for sustained growth, it notably failed tests related to Advertising and Research & Development to Assets. This score places JNJ just below the 80% threshold for 'some interest' within the model, indicating strong underlying fundamentals but specific concerns regarding future growth investment.

Analysis

Johnson & Johnson (JNJ) scores a 77% on Validea's P/B Growth Investor model, a quantitative strategy derived from Partha Mohanram's academic research designed to identify sustained-growth stocks. This score places JNJ just below the 80% threshold that indicates initial interest from the model. The analysis reveals a fundamentally strong profile, as JNJ passed key criteria including its book-to-market ratio, return on assets (ROA), cash flow from operations to assets, and low variance in both ROA and sales, suggesting operational stability and profitability. However, the model flagged two critical failures: insufficient spending on 'Advertising to Assets' and 'Research and Development to Assets'. For a strategy focused on identifying future growth drivers, these shortcomings are significant, suggesting that while JNJ is currently robust, its investment in future top-line growth through R&D and marketing may not meet the model's criteria for continued outperformance.

Key Decisions for Investors

• Growth-oriented investors should exercise caution, as the 77% score and failures in R&D and advertising investment metrics suggest JNJ may not meet the criteria for sustained high growth according to this specific model.
• Investors with a value or GARP (Growth at a Reasonable Price) focus may find the strong fundamentals, such as high return on assets and stable cash flows, to be attractive despite the moderate growth score.
• Monitor JNJ's future R&D and advertising expenditures relative to its asset base, as an increase in these areas could signal a strategic pivot towards accelerating growth and improve its screening on growth-focused models.